Stand Up: Third Parties May Challenge False Claims Act Civil Investigative Demands
Client Alert | 1 min read | 12.22.20
In General Medicine, P.C. v. United States, No. 3:20-mc-00053, the District Court for the Southern District of Illinois held that a third party has standing to challenge a False Claims Act (FCA) civil investigative demand (CID) that is issued to another entity. In that case, General Medicine, a company that employs physicians and nurse practitioners, petitioned the Court to set aside certain CIDs that were issued under the FCA to nursing facilities for which General Medicine provided services. General Medicine was the target of the Government’s investigation, and each of the CIDs sought information about General Medicine’s practices and involvement with the facility. In its petition, General Medicine argued that the CIDs issued to the nursing facilities were not sufficiently specific under the requirements of the FCA, did not seek information relevant to an investigation, and were overbroad and harassing. General Medicine also asserted that the Government had not issued the CIDs in “good faith” because they sought information that the Government already had in its possession. In response, the Government denied General Medicine’s points and argued that General Medicine lacked standing to bring a challenge under the FCA at all because it was not the recipient of the CIDs.
Finding that General Medicine had standing to bring the petition, the Court reasoned that while the FCA does not expressly state that a third party may bring a challenge, neither does the FCA prohibit a third party from doing so. The Court also noted that the Government failed to identify any other statute that “divests the Court of its authority to hear a third party’s objections to a subpoena,” particularly when a party’s “legitimate interests” would be infringed, as a CID is ultimately an administrative subpoena “by another name.”
While the petition was ultimately denied in General Medicine, the Court’s decision confirms that third parties do have opportunities to challenge CIDs that seek the third party’s information. The Government’s authority to issue CIDs is broad, but not boundless, and the General Medicine determination offers third parties welcome support to challenge CIDs.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection



